A detailed history of Jump Financial, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Jump Financial, LLC holds 141,978 shares of VRDN stock, worth $3.06 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
141,978
Previous 18,800 655.2%
Holding current value
$3.06 Million
Previous $244,000 1223.36%
% of portfolio
0.07%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.16 - $23.33 $1.5 Million - $2.87 Million
123,178 Added 655.2%
141,978 $3.23 Million
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.26 $218,080 - $324,488
18,800 New
18,800 $244,000
Q3 2023

Oct 21, 2024

BUY
$15.16 - $24.7 $191,364 - $311,788
12,623 Added 25.74%
61,654 $945,000
Q3 2023

Nov 07, 2023

BUY
$15.16 - $24.7 $191,364 - $311,788
12,623 Added 25.74%
61,654 $945,000
Q2 2023

Oct 21, 2024

SELL
$22.57 - $29.67 $61,300 - $80,583
-2,716 Reduced 5.25%
49,031 $1.17 Million
Q2 2023

Aug 07, 2023

SELL
$22.57 - $29.67 $61,300 - $80,583
-2,716 Reduced 5.25%
49,031 $1.17 Million
Q1 2023

Oct 21, 2024

BUY
$25.04 - $37.6 $824,992 - $1.24 Million
32,947 Added 175.25%
51,747 $1.32 Million
Q1 2023

May 03, 2023

BUY
$25.04 - $37.6 $549,928 - $825,771
21,962 Added 73.74%
51,747 $1.32 Million
Q4 2022

Feb 13, 2023

SELL
$18.78 - $29.74 $135,779 - $215,020
-7,230 Reduced 19.53%
29,785 $870,000
Q3 2022

Nov 07, 2022

BUY
$10.7 - $25.5 $111,140 - $264,868
10,387 Added 39.01%
37,015 $760,000
Q2 2022

Aug 09, 2022

BUY
$9.55 - $19.0 $254,297 - $505,932
26,628 New
26,628 $308,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $859M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.